Accellent to sell Pittsburgh facility to Perryman
Upon the completion of the sale, which is expected in the second quarter of 2012, the facility’s employees will become the employees of Perryman. Accellent president and CEO
The US Food and Drug Administration (FDA) is set to review Kowa Pharmaceuticals America’s new drug application (NDA) for K-911, an investigational once-daily eye drop aimed at reducing intraocular pressure (IOP) in open-angle glaucoma (OAG) or ocular hypertension (OHT) patients.